EQRx Inc is a biotechnology company. Its pipeline programs include two pre-registrational oncology assets that have shown assuring Phase 3 data (aumolertinib and sugemalimab), and multiple other clinical-stage programs.
Company
EQRx Inc is a biotechnology company. Its pipeline programs include two pre-registrational oncology assets that have shown assuring Phase 3 data (aumolertinib and sugemalimab), and multiple other clinical-stage programs.